Table 1.
Group | Control (n = 7) | HF (n = 12) | HTx (n = 12) | P-value (overall) |
---|---|---|---|---|
Age (years) | 42 ± 14 | 52 ± 16 | 47 ± 18 | >0.2 |
Gender n (%) | ||||
Male | 5 (71%) | 10 (83%) | 11 (92%) | >0.2 |
Female | 2 (29%) | 2 (17%) | 1 (8%) | |
BMI (kg/m2) | 27.8 ± 4.2 | 23.1 ± 3.1 | 31.5 ± 5.5 | <0.001 |
Cachexia presenta | NA | 7 (58%) | NA | NA |
Diabetes | 0 | 3 (25%) | 2 (17%) | NA |
Weight gain since HTx (kg) | NA | NA | 18.0 ± 7.7 | NA |
Time since HTx (months) | NA | NA | 12.7 ± 8.6 | NA |
Aetiology | ||||
Ischaemic | NA | 4 (33%) | 6 (50%) | >0.2 |
Dilated | 6 (50%) | 5 (42%) | ||
Valvular | 2 (17%) | 1 (8%) | ||
HF drug therapy | ||||
Loop diuretic | NA | 12 (100%) | NA | NA |
ACE-inhibitor | 12 (100%) | |||
Beta-blocker | 5 (42%) | |||
Inotropes | 7 (58%) | |||
HTx drug therapy | ||||
Prednisone (mg) | NA | NA | 6 ± 4 | NA |
Cyclosporine A | 9 (75%) | |||
Tacrolimus | 3 (25%) | |||
Mycophenolate mofetil | 12 (100%) |